Bal Pharma launches BALflu – generic of Covid-19 drug Favipiravir in India

Bal Pharma Ltd has launched its generic of the Covid-19 drug Favipiravir under the brand name BALflu in India.

Favipiravir has been used as an anti viral drug for the treatment of patients having mild to moderate Covid-19 infection. Its formulation is available in tablets form with a strength of 400 mg.

The Covid-19 drug works by blocking and terminating viral protein synthesis and by inducing lethal metagenesis of influenza virus.

See also  Veranda Learning to acquire 50% stake in Tapasya Educational Institutions for Rs 120cr
Bal Pharma launches BALflu – generic of Covid-19 drug Favipiravir in India
Bal Pharma launches BALflu – generic of Covid-19 drug Favipiravir in India. Image courtesy of visuals3Dde from Pixabay.

Favipiravir was approved by the Drug Controller General of India (DCGI) for emergency use for Covid treatment with a recommended dosage of 1800 mg on the first day after which 800 mg has to be taken from day 2 to 14.

Shailesh Siroya – Managing Director of Bal Pharma said that the BALflu has the efficacy to clear the novel coronavirus faster by 28.7%. BALflu cost is INR 85 per tablet and can be purchased as a prescription drug.

See also  Suven Life Sciences begins Masupirdine phase 3 clinical trial in dementia patients

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.